Drugs / Eprosartan
Eprosartan
also known as
Eprosartan mesilate · Eprosartan Mesylate · Eprosartan mesylate component of teveten hct · Eprosartan monomethanesulfonate · SK&F 108566 · SK&F 108566-J · SK-108566 · Teveten
Small molecule targets AGTR1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TEVETEN | — | 1998-10-28 | fda.gov ↗ |
| Approved | US (FDA) | TEVETEN | — | 1997-12-22 | fda.gov ↗ |
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01087749 | Mar 2010 → Dec 2012 | chronic kidney disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT04606563 | Oct 2020 → Apr 2022 | COVID-19 | University of British Columbia | Terminated | Missed primary |
| Phase 3 | NCT01631227 | Jun 2012 → Apr 2013 | essential hypertension | Abbott | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT00438945 | Jan 2007 → Jan 2008 | essential hypertension | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 4 | NCT00409903 | Nov 2006 → ? | — | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00160160 | Oct 2004 → ? | hypertensive disorder, type 2 diabetes mellitus | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 4 | NCT04394117 Comparator | Jun 2020 → Nov 2021 | COVID-19 | The George Institute | Completed | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| — | NCT04954560 Comparator | Jan 2008 → Jan 2010 | — | Medical University of Lodz | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eprosartan | “Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan” NCT04330300 ↗10“candesartan, eprosartan, irbesartan, losartan, olmesartan” NCT00684489 ↗ “Eprosartan 800mg/d” NCT02817360 ↗ |
| Known as | Eprosartan mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL813 ↗ |
| Known as | Eprosartan Mesylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01631227 ↗ |
| Known as | Eprosartan mesylate component of teveten hct | ChEMBL registry synonym — accepted as the source's own label CHEMBL813 ↗ |
| Known as | Eprosartan monomethanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL813 ↗ |
| Known as | SK&F 108566 | ChEMBL registry synonym — accepted as the source's own label CHEMBL813 ↗ |
| Known as | SK&F 108566-J | ChEMBL registry synonym — accepted as the source's own label CHEMBL813 ↗ |
| Known as | SK-108566 | ChEMBL registry synonym — accepted as the source's own label CHEMBL813 ↗ |
| Known as | Teveten | ChEMBL registry synonym — accepted as the source's own label CHEMBL813 ↗ |
| Action | Inhibit | “AT(1) receptor antagonists possess sympathoinhibitory effects in animal experiments, but in human studies the results are conflicting. We tested the hypothesis that very...” PMID 21640689 ↗ Jun 20111“Type-1 angiotensin II receptor antagonist” CHEMBL813 ↗ |
| Modality | Small molecule | — CHEMBL813 ↗ |
| Route | Oral | “Patients will initially receive initial dose of oral ARBs” NCT04606563 ↗ |
| Target | AGTR1 | “Type-1 angiotensin II receptor antagonist” CHEMBL813 ↗ |